Drug
firm Strides Arcolab's
manufacturing facility in
Bangalore has been approved by the US health regulator after a successful audit
of the plant, the company said on Friday.
"Oral
Dosage Forms manufacturing site (KRS Gardens) in Bangalore was recently
inspected by the US Food and Drug Administration (USFDA) as part of GMP
compliance audit and the facility continues to be approved," Strides
Arcolab said in a statement.
The
last USFDA inspection and approval for this facility was in the year 2011, it
added.
The KRS
Gardens facility in Bangalore manufactures oral dosage forms such as tablets,
capsules (both hard gelatine and soft gelatine) and sachets.
The
manufacturing plant supports important current and future submissions for the
US market, the company said.
Strides
Arcolab shares were
trading at Rs 505.35 apiece on the BSE in late afternoon trade, up 8.44 per
cent from its previous close.
No comments:
Post a Comment